Literature DB >> 17287053

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

H Nøkleby1, P Aavitsland, J O'Hallahan, B Feiring, S Tilman, P Oster.   

Abstract

MenBvac is an OMV vaccine against systemic serogroup B Neisseria meningitidis disease. MenBvac was developed for control of a B:15:P1.7,16 subtype epidemic in Norway and administered to 180,000 subjects in 28 clinical studies. MeNZB, a daughter vaccine of MenBvac, was developed for a clonal B:4:P1.7b,4 epidemic in New Zealand and administered to 1 million people <20 years. The vaccines were similar regarding reactogenicity profile. Serious adverse events (SAEs) in general and particularly neurologic SAEs were very rare. Despite frequently reported local reactions and fever in those under 5 years, these OMV-based vaccines containing 25 microg antigen can be considered safe for use in all age groups.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17287053     DOI： 10.1016/j.vaccine.2007.01.022

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  27 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 2.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

3.  A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.

Authors:  Oindrilla Mukherjee; Birendra Singh; Burcu Bayrak; Ann-Beth Jonsson; Matthias Mörgelin; Kristian Riesbeck
Journal:  Hum Vaccin Immunother       Date:  2015-06-04       Impact factor: 3.452

Review 4.  Proteomic contributions to our understanding of vaccine and immune responses.

Authors:  Allison C Galassie; Andrew J Link
Journal:  Proteomics Clin Appl       Date:  2015-09-10       Impact factor: 3.494

5.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

6.  Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.

Authors:  Chivonne Moodley; Mignon du Plessis; Kedibone Ndlangisa; Linda de Gouveia; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

7.  Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Authors:  Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff
Journal:  Vaccine       Date:  2011-05-13       Impact factor: 3.641

Review 8.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

9.  Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.

Authors:  Alan Kimura; Daniela Toneatto; Annett Kleinschmidt; Huajun Wang; Peter Dull
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

Review 10.  Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions.

Authors:  Carmen Schwechheimer; Meta J Kuehn
Journal:  Nat Rev Microbiol       Date:  2015-10       Impact factor: 60.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.